Table 2.
Viral coinfection in children with macrolide-resistant Mycoplasma pneumoniae pneumonia from studies published from 2018–2020
| Study | Nation | Study period | Cases studied viral coinfection (n) | Prevalence | Associated virus, detection rate among studied cases | Impact on clinical course |
|---|---|---|---|---|---|---|
| Zhao et al. [84] | China | 2016–2018 | 60 | 30.0% | PIV 11.7%, RSV 8.3%, AdV 8.3%, IFV 10% | Limited effects on the progression and prognosis of MRMP |
| Yan et al. [66] | 2013–2017 | 423 | 42.6%a) | PIV 6.6%, RSV 5.7%, AdV 5.0%, IFV 1.4% | Not mentioned | |
| Zhouv [24] | 2016–2019 | 107 (MRMP 60)b) | 56.1%b) | ADV 22.4%, PIV 13.1%, HRV/HEV 11.2%b) | Severe clinical course of MP pneumonia is associated with AdV coinfection. | |
| Lee and Lee [74] | Korea | 2019–2020 | 150 | 42.9% | AdV, HRVc) | Development of postinfectious bronchiolitis obliterans is associated with viral coinfection rather than MRMP. |
| Yang et al. [45] | Taiwan | 2010–2017 | 336 | 7.1% | AdV 7.1%, IFV 2.4%, RSV 0.9%, PIV 0.6% | Not mentioned |
| Hung et al. [75] | 2017–2019 | 226 | 17.7% | HRV 8.4%, AdV 4.0% | Not mentioned | |
| Rivaya et al. [80] | Spain | 2013–2017 | 137 | 45.3% | HRV 21.9%, PIV 8.8%, RSV 8.0% | Not mentioned |
| Waites et al. [16] | USA | 2015-2018 | 360 | 27.7% | HRV, HEV, IFV, PIV, AdV |
PIV, parainfluenza virus; RSV, respiratory syncytial virus; AdV, adenovirus; IFV, influenza virus; MRMP, macrolide-resistant Mycoplasma pneumoniae; HRV, human rhinovirus; HEV, human rhinoviruses; MP, Mycoplasma pneumoniae.
a)
Determined as a rate of coinfection with other pathogens.
b)
Determined as a rate of coinfection among whole patients with MP pneumonia.
c)
Detection rate on each respiratory virus was not specified.